Pentraxin 3 Is a Predictor for Fibrosis and Arterial Stiffness in Patients with Nonalcoholic Fatty Liver Disease

Gastroenterology Research and Practice

Volumn 2016, Issue , 2016, Pages

  Ozturk, Kadir ^a   Kurt, Omer ^a   Dogan, Tolga ^a   Ozen, Alptug ^a   Demirci, Hakan ^a   Yesildal, Fatih ^a   Kantarcioglu, Murat ^a   Turker, Turker ^a   Guler, Ahmet Kerem ^a   Karslioglu, Yildirim ^a   Altun, Battal ^b   Uygun, Ahmet ^a   Bagci, Sait ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b KASIMPASA MILITARY HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH SENSITIVE C REACTIVE PROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTRAXIN 3; UNCLASSIFIED DRUG; URIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR PARAMETERS; CAROTID FEMORAL PULSE WAVE VELOCITY; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW MEDIATED DILATATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HIP CIRCUMFERENCE; HUMAN; INSULIN BLOOD LEVEL; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL; PULSE WAVE; SMOKING; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84960968688     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2016/1417962     Document Type: Article

References (35)

1. P. Angulo, "Nonalcoholic fatty liver disease, " The New England Journal of Medicine, vol. 346, no. 16, pp. 1221-1231, 2002.
2. C. P. Day and O. F. W. James, "Steatohepatitis: A tale of two 'hits'?" Gastroenterology, vol. 114, no. 4, pp. 842-845, 1998.
3. G. C. Farrell, "Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?" Journal of Gastroenterology and Hepatology, vol. 18, no. 2, pp. 124-138, 2003.
4. P. Angulo, J. C. Keach, K. P. Batts, and K. D. Lindor, "Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis, " Hepatology, vol. 30, no. 6, pp. 1356-1362, 1999.
5. J.-F. Cadranel, "Good clinical practice guidelines for fine needle aspiration biopsy of the liver: Past, present and future, " Gastroenterologie Clinique et Biologique, vol. 26, no. 10, pp. 823-824, 2002.
6. H. Sakugawa, T. Nakayoshi, K. Kobashigawa et al., "Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease, " World Journal of Gastroenterology, vol. 11, no. 2, pp. 255-259, 2005.
7. T. Poynard, V. Ratziu, F. Charlotte et al., "Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease, " BMC Gastroenterology, vol. 6, article 34, 2006.
8. E. Napoleone, A. Di Santo, A. Bastone et al., "Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: A novel link between vascular inflammation and clotting activation, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 5, pp. 782-787, 2002.
9. C. Garlanda, B. Bottazzi, A. Bastone, and A. Mantovani, "Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility, " Annual Review of Immunology, vol. 23, pp. 337-366, 2005.
10. S. Matsui, J. Ishii, F. Kitagawa et al., "Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction, " Atherosclerosis, vol. 210, no. 1, pp. 220-225, 2010.
11. K. Ozturk, A. Uygun, A. K. Guler et al., "Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men, " Atherosclerosis, vol. 240, no. 2, pp. 380-386, 2015.
12. P. Nigam, S. P. Bhatt, A. Misra, M. Vaidya, J. Dasgupta, and D. S. Chadha, "Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: A case-control study on Asian Indians in North India, " PLoS ONE, vol. 8, no. 1, Article ID e49286, 2013.
13. I. Maleki, A. Rastgar, V. Hosseini et al., "High sensitive CRP and pentraxine 3 as noninvasive biomarkers of nonalcoholic fatty liver disease, " European ReviewforMedical and Pharmacological Sciences, vol. 18, no. 11, pp. 1583-1590, 2014.
14. M. Yoneda, T. Uchiyama, S. Kato et al., "Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH), " BMC Gastroenterology, vol. 8, article 53, 2008.
15. S. Boga, A. R. Koksal, H. Alkim et al., "Plasma pentraxin 3 differentiates nonalcoholic steatohepatitis (NASH) from non-NASH, " Metabolic Syndrome and Related Disorders, vol. 13, no. 9, pp. 393-399, 2015.
16. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, " Clinical Chemistry, vol. 18, no. 6, pp. 499-502, 1972.
17. American Diabetes Association, "Diagnosis and classification of diabetes mellitus, " Diabetes Care, vol. 37, supplement 1, pp. S81-S90, 2014.
18. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, "Homeostasis model assessment: insulin resistance and-cell function from fasting plasma glucose and insulin concentrations in man, " Diabetologia, vol. 28, no. 7, pp. 412-419, 1985.
19. D. E. Kleiner, E. M. Brunt, M. Van Natta et al., "Design and validation of a histological scoring systemfor nonalcoholic fatty liver disease, " Hepatology, vol. 41, no. 6, pp. 1313-1321, 2005.
20. J. Jou, S. S. Choi, and A. M. Diehl, "Mechanisms of disease progression in nonalcoholic fatty liver disease, " Seminars in Liver Disease, vol. 28, no. 4, pp. 370-379, 2008.
21. H. Tilg and A. R. Moschen, "Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis, " Hepatology, vol. 52, no. 5, pp. 1836-1846, 2010.
22. S. H. Park, B. I. Kim, J. W. Yun et al., "Insulin resistance and C-reactive protein as independent risk factors for nonalcoholic fatty liver disease in non-obese Asian men, " Journal of Gastroenterology and Hepatology, vol. 19, no. 6, pp. 694-698, 2004.
23. L. Deban, R. C. Russo, M. Sironi et al., "Regulation of leukocyte recruitment by the long pentraxin PTX3, " Nature Immunology, vol. 11, no. 4, pp. 328-334, 2010.
24. A. Parlak, A. Iyisoy, U. Aydogan, E. Cakir, and K. Saglam, "The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients, " Medical Hypotheses, vol. 79, no. 3, pp. 294-298, 2012.
25. A. Baragetti, M. Knoflach, I. Cuccovillo et al., "Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population, " Nutrition, Metabolism &Cardiovascular Diseases, vol. 24, no. 5, pp. 518-523, 2014.
26. E. Zimmermann, R. Anty, J. Tordjman et al., "C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients, " Journal ofHepatology, vol. 55, no. 3, pp. 660-665, 2011.
27. W. Dunn, R. Xu, D. L. Wingard et al., "Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study, " The American Journal of Gastroenterology, vol. 103, no. 9, pp. 2263-2271, 2008.
28. E. T. Oni, A. S. Agatston, M. J. Blaha et al., "A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?" Atherosclerosis, vol. 230, no. 2, pp. 258-267, 2013.
29. C. Vlachopoulos, E. Manesis, K. Baou et al., "Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: A pilot study, " American Journal of Hypertension, vol. 23, no. 11, pp. 1183-1189, 2010.
30. A. Miyaki, S. Maeda, Y. Choi et al., "Association of plasma pentraxin 3 with arterial stiffness in overweight and obese individuals, " American Journal of Hypertension, vol. 26, no. 10, pp. 1250-1255, 2013.
31. A. Zempo-Miyaki, S. Fujie, K. Sato et al., "Elevated pentraxin 3 level at theearly stage of exercise training is associated with reduction of arterial stiffness in middle-aged and older adults, " Journal of Human Hypertension, 2015.
32. T. Kasai, K. Inoue, T. Kumagai et al., "Plasma pentraxin3 and arterial stiffness in men with obstructive sleep apnea, "American Journal of Hypertension, vol. 24, no. 4, pp. 401-407, 2011.
33. Yasmin, C. M. McEniery, S. Wallace, I. S. Mackenzie, J. R. Cockcroft, and I. B. Wilkinson, "C-reactive protein is associated with arterial stiffness in apparently healthy individuals, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 5, pp. 969-974, 2004.
34. C. Vlachopoulos, I. Dima, K. Aznaouridis et al., "Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals, " Circulation, vol. 112, no. 14, pp. 2193-2200, 2005.
35. H. Ohbayashi, C. Miyazawa, K. Miyamoto, M. Sagara, T. Yamashita, and R. Onda, "Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia, " Journal of Atherosclerosis andThrombosis, vol. 16, no. 4, pp. 490-500, 2009.